Alzheimer's disease is chronic neurodegenerative disease. One of the hypotheses of the cause is high concentrations of Aβ accumulate in the brain. Transthyretin (TTR) is one of the Aβ-binding proteins. TTR binds to Aβ, prevents its aggregation and fibrillation, and consequently inhibits Aβ-induced cellular toxicity. TTR is a homotetrameric protein composed of four 127-amino-acid, β-sheet-rich subunits. The established physiological functions of TTR are to bind to and transport the thyroid hormone thyroxine (T4) and holo-retinol binding protein in the blood and cerebrospinal fluid (CSF).
According to the reported paper, cerebrospinal fluid (CSF) and plasma TTR levels were significantly lower in Alzheimer's disease, therefore serum TTR level has tremendous potential as one of the noninvasive diagnostic and prognostic biomarkers. So, we synthesis of compounds as a Alzheimer's disease biomarker.